Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $118.22 USD
Change Today +2.49 / 2.15%
Volume 4.3M
CELG On Other Exchanges
Symbol
Exchange
Frankfurt
NASDAQ GM
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000

Fax:

gh-risk MDS, according to the National Comprehensive Cancer Network. In 2013, the company also contracted with Sandoz AG to sell a generic version of VIDAZA in the United States, which the company supplies. Regulatory exclusivity for VIDAZA is expected to continue in Europe through 2018. VIDAZA is marketed in the United States and various international markets for the treatment of patients with MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia. azacitidine for injection (generic version of VIDAZA): The company contracted with Sandoz AG to sell azacitidine for injection, which they launched after the introduction of a generic version of VIDAZA in the United States by a competitor in September 2013. THALOMID (thalidomide): THALOMID, sold as THALOMID or Thalidomide Celgene outside of the United States, is administered orally for the treatment of diseases, such as multiple myeloma and erythema nodosum leprosum. THALOMID is distributed in the United States under the company’s THALOMID REMS program, which is a proprietary risk-management distribution program tailored primarily to provide for the safe and appropriate distribution and use of THALOMID. Internationally, THALOMID and Thalidomide Celgene are also distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the safe and appropriate distribution and use of THALOMID and Thalidomide Celgene. OTEZLA (apremilast): OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. During 2014 and January 2015, OTEZLA received initial approvals in the U.S. and EU. OTEZLA is used to treat patients with psoriatic arthritis and psoriasis. ISTODAX (romidepsin): ISTODAX is administered by intravenous infusion for the treatment of diseases (cutaneous T-cell lymphoma and peripheral T-cell lymphoma) and has received orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma. FOCALIN, FOCALIN XR, and RITALIN LA: The company licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis Pharma AG (Novartis). The company also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products, which are used in FOCALIN XR and RITALIN LA. Preclinical and Clinical-Stage Pipeline The company’s preclinical and clinical-stage pipeline of new drug candidates and cell therapies is highlighted by multiple classes of both small molecule and biologic therapeutic agents designed to selectively regulate disease-associated genes and proteins. These product candidates are at various stages of preclinical and clinical development. Oral Anti-Inflammatory Agents: The company is developing novel, orally administered small molecules that primarily target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes, and nitric oxide synthase. Next Generation of Cereblon Modulatory Drugs: CC-122 (a PPM Pleiotropic Pathway Modifier) and CC-220 represent novel compounds that are in phase I clinical trials for hematological and solid tumor cancers, and inflammation and immunology diseases. They have been differentiated from previous compounds (such as Thalidomide, Lenalidomide, and Pomalidomide) and have been developed based on the company’s scientific understanding of Cereblon-mediated protein homeostasis. Cellular Therapies: At Celgene Cellular Therapeutics (CCT), the company is conducting research with stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the company’s research and development division dedicated to fulfilling the promise of cellular technologies by developing products and therapies to benefit patients. Stem cell based therapies offer the potential to provide disea

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $118.22 USD +2.49

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $405.41 USD +1.47
Bristol-Myers Squibb Co $67.67 USD +1.13
Eli Lilly & Co $84.85 USD +1.36
Shire PLC 5,210 GBp +115.00
Valeant Pharmaceuticals International Inc C$277.47 CAD +4.61
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 39.5x
Price/Sales 11.5x
Price/Book 13.6x
Price/Cash Flow 34.1x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.